Aliases & Classifications for Burns

Summaries for Burns

MedlinePlus : 44 A burn is damage to your body's tissues caused by heat, chemicals, electricity, sunlight, or radiation. Scalds from hot liquids and steam, building fires and flammable liquids and gases are the most common causes of burns. Another kind is an inhalation injury, caused by breathing smoke. There are three types of burns: First-degree burns damage only the outer layer of skin Second-degree burns damage the outer layer and the layer underneath Third-degree burns damage or destroy the deepest layer of skin and tissues underneath Burns can cause swelling, blistering, scarring and, in serious cases, shock, and even death. They also can lead to infections because they damage your skin's protective barrier. Treatment for burns depends on the cause of the burn, how deep it is, and how much of the body it covers. Antibiotic creams can prevent or treat infections. For more serious burns, treatment may be needed to clean the wound, replace the skin, and make sure the patient has enough fluids and nutrition. NIH: National Institute of General Medical Sciences

MalaCards based summary : Burns, also known as burn, is related to complex regional pain syndrome and irritant dermatitis. An important gene associated with Burns is TTR (Transthyretin), and among its related pathways/superpathways are MAPK signaling pathway and T cell receptor signaling pathway. The drugs Tranexamic Acid and Amikacin have been mentioned in the context of this disorder. Affiliated tissues include Umbilical Cord, skin and eye, and related phenotypes are Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) and cardiovascular system

Related Diseases for Burns

Diseases related to Burns via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 893)
# Related Disease Score Top Affiliating Genes
1 complex regional pain syndrome 32.1 IL1B TNF
2 irritant dermatitis 32.0 IL1B TNF
3 glossitis 31.8 IL1B TNF TTR
4 vulvar vestibulitis syndrome 31.5 IL1B TNF
5 carpal tunnel syndrome 31.4 IL1B INS TTR
6 pyelonephritis 31.1 ALB IL1B TNF
7 peripheral nervous system disease 31.1 ALB INS TNF TTR
8 compartment syndrome 30.6 ALB TNF
9 toxic shock syndrome 30.5 IL1B SERPINC1 TNF
10 chronic ulcer of skin 30.3 ALB TTR
11 bacterial infectious disease 30.1 CSF2 IL1B TNF
12 decubitus ulcer 30.1 ALB TTR
13 respiratory failure 30.1 ALB TNF TTR
14 fournier gangrene 30.0 ALB SERPINC1
15 staphylococcal toxic shock syndrome 29.9 IL1B TNF
16 critical limb ischemia 29.9 HGF TNF
17 lung disease 29.8 CSF2 IL1B TNF
18 trichosporonosis 29.7 CSF2 TNF
19 kwashiorkor 29.6 ALB TTR
20 haemophilus influenzae 29.6 IL1B TNF
21 thyroid crisis 29.6 ALB TTR
22 meningitis 29.6 ALB IL1B TNF
23 stomatitis 29.5 CSF2 IL1B TNF
24 euthyroid sick syndrome 29.5 ALB IL1B
25 duodenal ulcer 29.5 IL1B INS TNF
26 rheumatoid arthritis 29.4 CSF2 IL1B TNF TTR
27 protein-energy malnutrition 29.3 ALB TNF TTR
28 arthritis 29.3 CSF2 IL1B TNF
29 endocarditis 29.3 ALB SERPINC1 TNF
30 acute kidney tubular necrosis 29.3 ALB HGF
31 fatty liver disease 29.3 IL1B INS TNF
32 aphthous stomatitis 29.3 IL1B TNF
33 diabetes mellitus 29.3 ALB IL1B INS TNF
34 nonalcoholic steatohepatitis 29.3 INS TNF
35 appendicitis 29.2 ALB IL1B TNF
36 acute liver failure 29.2 ALB HGF
37 chronic fatigue syndrome 29.2 CRH IL1B TNF
38 aplastic anemia 29.1 ALB CSF2 TNF
39 acquired immunodeficiency syndrome 29.1 ALB CSF2 IL1B TNF
40 pulmonary fibrosis, idiopathic 29.1 HGF IL1B TNF
41 sleep apnea 28.9 IL1B INS TNF
42 autoimmune disease 28.9 IL1B INS TNF
43 liver disease 28.7 ALB HGF INS TNF
44 myocardial infarction 28.6 ALB IL1B INS SERPINC1 TNF
45 arteries, anomalies of 28.2 ALB IL1B INS SERPINC1 TNF
46 heart disease 28.2 ALB IL1B INS SERPINC1 TNF
47 gastrointestinal system disease 28.1 ALB CRH IL1B INS TNF
48 burning mouth syndrome 12.6
49 burn-mckeown syndrome 12.6
50 burn scar 12.3

Graphical network of the top 20 diseases related to Burns:



Diseases related to Burns

Symptoms & Phenotypes for Burns

GenomeRNAi Phenotypes related to Burns according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 8.8 CSF2 INS TNF

MGI Mouse Phenotypes related to Burns:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.91 CSF2 HGF IL1B INS SERPINC1 TNF
2 hematopoietic system MP:0005397 9.87 CRH CSF2 HGF IL1B INS SERPINC1
3 homeostasis/metabolism MP:0005376 9.86 ALB CRH CSF2 IL1B INS SERPINC1
4 liver/biliary system MP:0005370 9.63 ALB CRH HGF INS SERPINC1 TNF
5 no phenotypic analysis MP:0003012 9.35 CRH HGF INS TNF TTR
6 renal/urinary system MP:0005367 9.1 ALB CRH CSF2 INS SERPINC1 TTR

Drugs & Therapeutics for Burns

Drugs for Burns (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1078)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Tranexamic Acid Approved Phase 4,Phase 3,Phase 2,Not Applicable 1197-18-8 5526
2
Amikacin Approved, Investigational, Vet_approved Phase 4,Not Applicable 37517-28-5 37768
3 silver nitrate Approved, Investigational Phase 4,Phase 3,Phase 2
4
Bacitracin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1405-87-4 10909430 439542
5
Hydrocortisone acetate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-03-3
6
Hydrocortisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Not Applicable 50-23-7 5754
7 Parthenolide Approved, Investigational Phase 4,Phase 3 20554-84-1
8
Bronopol Approved Phase 4,Phase 3,Phase 2 52-51-7
9
Carboprost tromethamine Approved Phase 4 58551-69-2 35023177 5284525
10
Dexmedetomidine Approved, Vet_approved Phase 4,Phase 2,Phase 1 113775-47-6 5311068 68602
11
Racepinephrine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 329-65-7 838
12
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 137-58-6 3676
13
Epinephrine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 51-43-4 5816
14
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 437-38-7 3345
15
Tocopherol Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 1406-66-2 14986
16
Chlorhexidine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 55-56-1 2713 9552079
17
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
18
Fluticasone Approved, Experimental Phase 4,Phase 3,Phase 2 90566-53-3 62924
19
Benzoyl peroxide Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 94-36-0 7187
20
Clindamycin Approved, Vet_approved Phase 4,Phase 3,Phase 2 18323-44-9 29029
21
Aminolevulinic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 106-60-5 137
22
Angiotensin II Approved, Investigational Phase 4,Phase 2,Phase 3 11128-99-7, 68521-88-0, 4474-91-3 172198
23
Donepezil Approved Phase 4,Phase 3 120014-06-4 3152
24
Midazolam Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 59467-70-8 4192
25
Remifentanil Approved Phase 4,Not Applicable 132875-61-7 60815
26
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
27
Chlorthalidone Approved Phase 4 77-36-1 2732
28
Aspirin Approved, Vet_approved Phase 4,Phase 3 50-78-2 2244
29
Atorvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1 134523-00-5 60823
30
Sulfadiazine Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 68-35-9 5215
31
Silver sulfadiazine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 22199-08-2 441244
32
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 1994-09-7, 94-09-7 2337
33
tannic acid Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 1401-55-4
34
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 9005-49-6 46507594 772
35
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 124-94-7 31307
36
Metronidazole Approved Phase 4,Phase 2,Phase 3,Not Applicable 443-48-1 4173
37
Povidone-iodine Approved Phase 4,Not Applicable 25655-41-8
38
Iodine Approved, Investigational Phase 4,Phase 2,Not Applicable 7553-56-2 807
39
Povidone Approved Phase 4,Phase 3,Phase 2,Not Applicable 9003-39-8
40
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 9004-61-9 53477741
41
Pioglitazone Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 111025-46-8 4829
42
Hydrogen peroxide Approved, Vet_approved Phase 4,Not Applicable 7722-84-1 784
43
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-45-6 774
44
Methylcobalamin Approved, Experimental, Investigational Phase 4,Phase 3,Not Applicable 13422-55-4
45
Hydroxocobalamin Approved Phase 4,Phase 3,Not Applicable 13422-51-0 15589840 11953898
46
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 58-05-9 143 6006
47
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Not Applicable 103-90-2 1983
48
Benzydamine Approved Phase 4,Phase 3,Phase 1 642-72-8, 100-46-9 7504
49
Minocycline Approved, Investigational Phase 4,Not Applicable 10118-90-8 5281021
50
Doxycycline Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 564-25-0 54671203

Interventional clinical trials:

(show top 50) (show all 2226)
# Name Status NCT ID Phase Drugs
1 TRANexamic Acid to Reduce Bleeding in BURN Surgery Unknown status NCT03113253 Phase 4 Tranexamic Acid;Placebo
2 Hypoalbuminemia in Burn Patients Unknown status NCT01436292 Phase 4 5% human albumin solution (HAS)
3 Early Fluid Resuscitation With Balanced HES 130/0.4 [6%] in Severe Burn Injury Unknown status NCT01012648 Phase 4 Fluid resuscitation;HES 130/0.4 (6%), Voluven balanced vs. Lactated Ringer's solution
4 Amikacin Pharmacokinetic Profile in Plasma and Tissue After an Administration Using Impregnated Dressings in Burned Patient Population Unknown status NCT02872272 Phase 4 Treatment with Amikacin
5 The Treatment of Bartholin´s Cyst or Abscess With Silver Nitrate Unknown status NCT00786461 Phase 4
6 Clinical Evaluation of T.R.U.E. Test Allergens in Children an Adolescents Unknown status NCT01797562 Phase 4 T.R.U.E. Test Panel 3.2
7 Evaluate the Efficacy, Safety and Tolerability of a Non-hormonal Intravaginal Gel in Postmenopausal Women With Symptoms of Vaginal Dryness. Unknown status NCT02571127 Phase 4 Hidra1
8 Dexmedetomidine on Prevention of Side Effects of Hemabate Unknown status NCT02220361 Phase 4 placebo;low dose dexmedetomidine;high dose dexmedetomidine
9 TRPV Expression in Subjects With Sensitive Skin Unknown status NCT01871883 Phase 4
10 Intranasal Fentanyl for Pain Management Unknown status NCT00882960 Phase 4 intravenous fentanyl;intra-nasal fentanyl
11 Oral Nutrition Impact on Tear Film Unknown status NCT01561040 Phase 4
12 Trial on the Efficacy of Tegaderm Chlorhexidine Gluconate (CHG) in Reducing Catheter Related Bloodstream Infections Unknown status NCT01142934 Phase 4
13 Effect of Fluticasone Proprionate 0.05% on Narrow Band UV-B in Active Vitiligo Unknown status NCT01246921 Phase 4 Fluticasone proprionate 0.05% cream
14 Safety and Tolerability of Acanya Gel in Combination With Atralin Gel for Acne Vulgaris Unknown status NCT01448733 Phase 4 Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning with with tretinoin 0.05% gel in the evening
15 Superficial Basal Cell Carcinoma Treatment With Topical Photodynamic Therapy With Fractionated 5-aminolevulinic Acid 20% Versus Two Stage Methylaminolevulinate Unknown status NCT01491711 Phase 4 Methylaminolevulinate PDT in 2 sessions;Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT
16 Perception of Efficacy, Safety and Tolerability of Three Non-hormonal Intravaginal Gels and Hormone Cream Unknown status NCT02987647 Phase 4
17 Postoperative Pain and Angiotensin II Receptor Antagonists Unknown status NCT02513979 Phase 4 Angiotensin type II receptor antagonists
18 CALM-AD Unknown status NCT00142324 Phase 4 Donepezil
19 The Effect of High-dose Remifentanil on Established Sunburn-induced Hyperalgesia in Human Volunteers (HighDose RemiSun) Unknown status NCT01015482 Phase 4 Remifentanil;Midazolam
20 The Effect of Remifentanil on Established Sunburn-induced Hyperalgesia in Human Volunteers Unknown status NCT00811837 Phase 4 Midazolam;Remifentanil
21 Management of Chronic Pain in Military Patients With Injuries Sustained During Active Duty Unknown status NCT01616342 Phase 4
22 Chlorthalidone and HCTZ Impacts on Platelet Activation Unknown status NCT02100462 Phase 4 Chlorthalidone 12.5 mg;Hydrochlorothiazide 25 mg;Aspirin 81 mg
23 Intensive Statin Therapy Effect on Post-Operative Atrial Fibrillation (POAF) Unknown status NCT02029534 Phase 4 Atorvastatin 20 mg;Atorvastatin 80 mg
24 Treatment of Facial Burns With Flammacerium Compared to Flammazine and the Impact of Facial Burns on Psychosocial Wellbeing Completed NCT00297752 Phase 4 ceriumnitrate silversulfadiazine (flammacerium);silversulfadiazine (flammazine)
25 The Effect of Two Versus Ten Days Application of Flammacerium in Partial Thickness Burns Completed NCT00156988 Phase 4 cerium nitrate-silver sulfadiazine (cerium-flamazine)
26 Pharmacokinetics Ertapenem Burns Completed NCT01497990 Phase 4 Ertapenem
27 Comparative Analysis of Cost-effectiveness of Silver Dressing in Burns Completed NCT02108535 Phase 4 Nanocrystalline silver;Silver Sulphadiazine
28 Efficacy and Safety Study of rhGM-CSF Gel to Treat Deep 2nd Thickness Burn Completed NCT01785784 Phase 4 rhGM-CSF Gel
29 Comparison of Wound Bed Establishment in Facial Burns Completed NCT01668030 Phase 4 Enzymatic agent;Bacitracin
30 Continuous Lidocaine Infusion for Management of Perioperative Burn Pain Completed NCT02059902 Phase 4 Lidocaine
31 Comparison of a Water-soluble Topical Antimicrobial to Silver Sulfadiazine in Partial Thickness Burns Completed NCT01926392 Phase 4 water-soluble therapy;silver sulfadiazine
32 Evaluation of Post Burn Rehabilitation Population for Itch Control Completed NCT00782054 Phase 4
33 An Acellular Epithelial Skin Substitute in Deep Partial-thickness Burns Completed NCT01454310 Phase 4
34 Effect of Early Enteral Tube Feeding Nutrition With an Immune Enhancing Diet in Severe Burn Patients Completed NCT00561210 Phase 4
35 Low-dose Hydrocortisone in Acutely Burned Patients Completed NCT00149123 Phase 4 hydrocortisone 200 mg/day
36 Caustic Esophageal Burns in Children and High Doses of Methylprednisolone Completed NCT02002078 Phase 4 methylprednisolon
37 Effect of Silicone Gel Versus Contractubex Phonophoresis for Post-burn Hypertrophic Scars Completed NCT03777891 Phase 4
38 Open, Prosp, Rand. Invest. Evaluating Pain With Mepitel One vs.Bridal Veil and Staples on Split Thickness Skin Grafts Completed NCT01365273 Phase 4
39 Safety and Immunogenicity Study of Recombinant Thrombin (rThrombin) in Pediatric Participants Completed NCT00859547 Phase 4
40 Ethnic Differences in Response to Topical Capsaicin: A Psychophysical Study on Healthy Subjects Completed NCT00655811 Phase 4 Capsaicin;Placebo moisturizing cream
41 Split-face Tolerability Comparison Between MetroGel® 1% vs Finacea® 15% in Subjects With Healthy Skin Completed NCT01139047 Phase 4 metronidazole 1% gel;azelaic acid 15% gel
42 Split-Face Tolerability Comparison Between MetroGel® 1% Versus Finacea® 15% in Subjects With Healthy Skin Completed NCT01139008 Phase 4 metronidazole 1% gel;azelaic acid 15% gel
43 Split-face Tolerability Comparison Between Adapalene-Benzoyl Peroxide Gel Versus Tretinoin Gel Completed NCT01522456 Phase 4 Epiduo Gel;Retin-A Micro Microsphere 0.1%
44 A Clinical Trial to Study the Effects of Two Drugs, Lycopene and Prednisolone in Patients With Oral Lichen Planus Completed NCT02587117 Phase 4 lycopene;Prednisolone
45 Tolerance of Chlorhexidine Gluconate Vaginal Cleansing Solution Completed NCT03305159 Phase 4 Povidone-Iodine;4% Chlorhexidine Gluconate
46 Evaluation of Irritation by Two Facial Gels Applied to Opposite Sides of the Face Completed NCT00919191 Phase 4 Tretinoin gel;Adapalene and Benzoyl peroxide
47 Aruba Aloe Formula F-BC-096 in the Treatment of Split Thickness Donor Site After Wound Closure Completed NCT01213420 Phase 4
48 A Study of Sertraline to Prevent PTSD Completed NCT00182078 Phase 4 Placebo;Sertraline
49 Effect of Topically-Applied Hyaluronic-Acid on Palatal Epithelial Wound Closure Completed NCT02534415 Phase 4 Periodontal dressing material;0.2% Hyaluronic acid gel;0.8% Hyaluronic acid gel
50 Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration Completed NCT01161563 Phase 4 Triptorelin pamoate;Leuprolide acetate

Search NIH Clinical Center for Burns

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Burns cell therapies at LifeMap Discovery.

Genetic Tests for Burns

Anatomical Context for Burns

MalaCards organs/tissues related to Burns:

42
Skin, Eye, Breast, Testes, Lung, Bone, Brain
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Burns:
# Tissue Anatomical CompartmentCell Relevance
1 Umbilical Cord Wharton's Jelly Mesenchymal Stem Cells Potential therapeutic candidate

Publications for Burns

Articles related to Burns:

(show top 50) (show all 6153)
# Title Authors Year
1
Red blood cell distribution width is an independent risk factor in the prediction of acute respiratory distress syndrome after severe burns. ( 30686695 )
2019
2
Effectiveness of ECMO for burn-related acute respiratory distress syndrome. ( 30429074 )
2019
3
The effect of early change of skin graft dressing on pain and anxiety among burn patients: a two-group randomized controlled clinical trial. ( 30911431 )
2019
4
Examining the Rates of Anxiety, Depression, and Burnout Among Providers at a Regional Burn Center. ( 30032292 )
2019
5
Atrial Fibrillation: Rate, Rhythm, and Burn. ( 31072704 )
2019
6
Evaluation of Procalcitonin Accuracy for the Distinction Between Gram-Negative and Gram-Positive Bacterial Sepsis in Burn Patients. ( 30481299 )
2019
7
Challenges to the Standardization of Trauma Data Collection in Burn, Traumatic Brain Injury, Spinal Cord Injury, and Other Trauma Populations: A Call for Common Data Elements for Acute and Longitudinal Trauma Databases. ( 31030731 )
2019
8
Steam burn as a late complication of nonsensate DIEP flap after breast reconstruction. ( 30672014 )
2019
9
A case of herpes simplex virus reactivation after fractional ablative carbon dioxide laser to treat a burn scar. ( 30019972 )
2019
10
Combined Non-Ablative Laser and Microfat Grafting for Burn Scar Treatment. ( 30403775 )
2019
11
Malignant melanoma on a thermal burn scar. ( 30703864 )
2019
12
Verrucous carcinoma: An unexpected finding arising from a burn scar. ( 30809566 )
2019
13
A Review of Perforator Flaps for Burn Scar Contractures of Joints. ( 30854364 )
2019
14
Goniometric measurement of burn scar contracture: a paradigm shift challenging the standard. AUTHORS. ( 30919903 )
2019
15
The prevalence and development of burn scar contractures: A prospective multicenter cohort study. ( 30948277 )
2019
16
Treating Hypertrophic Burn Scar With 2940-nm Er:YAG Laser Fractional Ablation Improves Scar Characteristics as Measured by Noninvasive Technology. ( 31046088 )
2019
17
Quantification of Pediatric Burn Scar Stiffness Using Acoustic Radiation Force Impulse Ultrasound Elastography. ( 31104865 )
2019
18
Ablative fractional resurfacing in acute care management of facial burns: a new approach to minimise the need for acute surgical reconstruction. ( 30847482 )
2019
19
High prevalence of imipenem-resistant and metallo-beta-lactamase-producing Pseudomonas aeruginosa in the Burns Hospital in Tunisia: detection of a novel class 1 integron. ( 30849001 )
2019
20
Five Years Experience With Meek Grafting in the Management of Extensive Burns in an Adult Burn Center. ( 30854361 )
2019
21
Does Increased Patient Load Improve Mortality in Burns?: Identifying Benchmark Parameters Defining Quality of Burn Care. ( 30855365 )
2019
22
Adherence to Treatment and Follow-Up in Patients with Severe Chemical Eye Burns. ( 30868417 )
2019
23
The Quality of Life in Women with Burns in Iran. ( 30873360 )
2019
24
Long noncoding RNA MALAT1 regulates sepsis in patients with burns by modulating miR‑214 with TLR5. ( 30896848 )
2019
25
Acellular Fish Skin Grafts for Management of Split Thickness Donor Sites and Partial Thickness Burns: A Case Series. ( 30901429 )
2019
26
Comparative study of silver-sulfadiazine-impregnated collagen dressing versus conventional burn dressings in second-degree burns. ( 30911509 )
2019
27
Photobiomodulation of red and green lights in the repair process of third-degree skin burns. ( 30919284 )
2019
28
Admission factors associated with the in-hospital mortality of burns patients in resource-constrained settings: A two-year retrospective investigation in a South African adult burns centre. ( 30928024 )
2019
29
Inadvertent macular burns and consecutive psychological depression secondary to Alexandrite laser epilation: A case report. ( 30930674 )
2019
30
Pearls & Oy-sters: Bismuth neurotoxicity from use of topical bismuth dressing for burns. ( 30936231 )
2019
31
Congenital Laser-Induced Burns: A Potential Complication after Laser Photocoagulation in Monochorionic Twin Pregnancy. ( 30942125 )
2019
32
Efficacy and safety of basic fibroblast growth factor in the treatment of burns: Protocol for a systematic review and meta-analysis of randomized controlled trials. ( 30946374 )
2019
33
Supporting children with burns: Developing a UK parent-focused peer-informed website to support families of burn-injured children. ( 30962077 )
2019
34
Effectiveness of Parkland formula in the estimation of resuscitation fluid volume in adult thermal burns. ( 30962126 )
2019
35
Negative pressure wound therapy versus microcurrent electrical stimulation in wound healing in burns. ( 30975055 )
2019
36
Evaluation of the efficacy of Hypericum perforatum (St. John's wort) oil in the prevention of stricture due to esophageal corrosive burns. ( 30976959 )
2019
37
Using Bioactive Glasses in the Management of Burns. ( 30984751 )
2019
38
Management of Major Burns in 37 Casualties of a Colored Powder Explosion: Experience of the Linkou Burn Center in Taiwan. ( 30985342 )
2019
39
A systematic review of foam dressings for partial thickness burns. ( 31000315 )
2019
40
Burns Awareness Day - Letter To Editors. ( 31000877 )
2019
41
Use of Silver-Containing Hydrofiber and Chlorhexidine-Impregnated Tulle Gras Dressings for Second-Degree Burns. ( 31008744 )
2019
42
MHRA drug safety update: severe and fatal burns risk with emollients. ( 31018926 )
2019
43
Gluteal Burns from a Car Seat Heater in a Neurologically Intact Patient: A Case Report. ( 31023634 )
2019
44
Excision and direct closure of burns - A proposed wound follow-up protocol. ( 31029584 )
2019
45
Reconstruction of the distal leg and foot using free anterolateral thigh flaps in patients with high-voltage electrical burns. ( 31032512 )
2019
46
Toxic Epidermal Necrolysis Therapy with TPE and IVIG - Ten Years of Experience of the Burns Treatment Center. ( 31032516 )
2019
47
Treatment for Pyogenic Granuloma after Burns: A Retrospective, Single-Center Study Involving 15 Cases. ( 31043222 )
2019
48
Burns in practice of helicopter emergency medical service in Poland. Retrospective analysis. ( 31051005 )
2019
49
Electrical Burns During Fruit Harvesting. ( 31051035 )
2019
50
Adapting prescribed burns to future climate change in Mediterranean landscapes. ( 31051384 )
2019

Variations for Burns

Expression for Burns

Search GEO for disease gene expression data for Burns.

Pathways for Burns

Pathways related to Burns according to GeneCards Suite gene sharing:

(show all 27)
# Super pathways Score Top Affiliating Genes
1 12.54 HGF IL1B INS TNF
2
Show member pathways
12.35 CSF2 IL1B TNF
3
Show member pathways
12.11 CSF2 IL1B TNF
4
Show member pathways
12.04 ALB IL1B INS TNF
5 11.87 ALB HGF INS
6
Show member pathways
11.83 CSF2 IL1B TNF
7 11.78 HGF IL1B TNF
8 11.75 CSF2 IL1B TNF
9 11.69 CSF2 IL1B TNF
10 11.67 CSF2 IL1B TNF
11 11.63 CSF2 IL1B TNF
12 11.52 CSF2 IL1B TNF
13 11.48 CSF2 IL1B TNF
14
Show member pathways
11.41 CSF2 IL1B TNF
15 11.23 CSF2 IL1B TNF
16 11.2 IL1B TNF
17 11.19 HGF IL1B TNF
18 11.17 IL1B TNF
19 11.12 IL1B TNF
20 11.1 IL1B TNF
21 11.08 ALB INS TTR
22 10.94 IL1B TNF
23 10.8 CSF2 HGF IL1B TNF
24 10.79 IL1B TNF
25 10.72 CSF2 HGF IL1B TNF
26 10.69 CSF2 HGF IL1B TNF
27 10.59 CSF2 IL1B TNF

GO Terms for Burns

Cellular components related to Burns according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 ALB CRH CSF2 HGF IL1B INS
2 extracellular space GO:0005615 9.28 ALB CRH CSF2 HGF IL1B INS

Biological processes related to Burns according to GeneCards Suite gene sharing:

(show all 37)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.93 CRH CSF2 IL1B INS
2 positive regulation of cell migration GO:0030335 9.84 HGF IL1B INS
3 cytokine-mediated signaling pathway GO:0019221 9.84 CSF2 HGF IL1B TNF
4 positive regulation of protein kinase B signaling GO:0051897 9.8 HGF INS TNF
5 cellular response to lipopolysaccharide GO:0071222 9.8 CSF2 IL1B TNF
6 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.78 IL1B INS TNF
7 activation of MAPK activity GO:0000187 9.75 HGF IL1B TNF
8 MAPK cascade GO:0000165 9.73 CSF2 HGF IL1B TNF
9 cellular protein metabolic process GO:0044267 9.71 ALB INS SERPINC1 TTR
10 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.69 HGF INS TNF
11 positive regulation of phagocytosis GO:0050766 9.67 IL1B TNF
12 protein kinase B signaling GO:0043491 9.67 IL1B TNF
13 lipopolysaccharide-mediated signaling pathway GO:0031663 9.67 IL1B TNF
14 negative regulation of interleukin-6 production GO:0032715 9.66 HGF TNF
15 positive regulation of cytokine secretion GO:0050715 9.65 INS TNF
16 positive regulation of interleukin-8 production GO:0032757 9.65 IL1B TNF
17 positive regulation of mitotic nuclear division GO:0045840 9.65 IL1B INS
18 negative regulation of neurogenesis GO:0050768 9.64 IL1B TNF
19 positive regulation of glial cell proliferation GO:0060252 9.62 IL1B TNF
20 positive regulation of protein phosphorylation GO:0001934 9.62 CRH HGF IL1B TNF
21 regulation of I-kappaB kinase/NF-kappaB signaling GO:0043122 9.61 IL1B TNF
22 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.6 IL1B TNF
23 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.59 IL1B TNF
24 regulation of protein secretion GO:0050708 9.58 INS TNF
25 positive regulation of podosome assembly GO:0071803 9.57 CSF2 TNF
26 positive regulation of chemokine biosynthetic process GO:0045080 9.56 IL1B TNF
27 regulation of establishment of endothelial barrier GO:1903140 9.55 IL1B TNF
28 positive regulation of gene expression GO:0010628 9.55 CRH CSF2 IL1B INS TNF
29 positive regulation of neuroinflammatory response GO:0150078 9.52 IL1B TNF
30 positive regulation of fever generation GO:0031622 9.49 IL1B TNF
31 sequestering of triglyceride GO:0030730 9.46 IL1B TNF
32 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.43 CSF2 IL1B TNF
33 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.37 IL1B TNF
34 response to immobilization stress GO:0035902 9.34 CRH
35 chronic inflammatory response to antigenic stimulus GO:0002439 9.18 TNF
36 negative regulation of lipid catabolic process GO:0050995 9.13 IL1B INS TNF
37 regulation of signaling receptor activity GO:0010469 9.1 CSF2 HGF IL1B INS TNF TTR

Molecular functions related to Burns according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.43 CSF2 IL1B TNF
2 hormone activity GO:0005179 9.33 CRH INS TTR
3 protease binding GO:0002020 9.13 INS SERPINC1 TNF
4 identical protein binding GO:0042802 9.1 ALB HGF INS SERPINC1 TNF TTR

Sources for Burns

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....